SCHEMBL2247137

SCHEMBL2247137

Clc1ccc(Cn2ccc3ccccc32)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.72
KMT2A Q03164 2/20 0.67
PLAU P00749 1/20 0.62
HDAC1 Q13547 2/20 0.59
HDAC2 Q92769 2/20 0.59
HDAC8 Q9BY41 2/20 0.59
HDAC6 Q9UBN7 2/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC9 Q9UKV0 1/20 0.59
CDK4 P11802 4/20 0.57
CCND1 P24385 4/20 0.57
BIRC5 O15392 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
HDAC3 O15379 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29459650 1.00 HTR6 (0.72) HTR6KMT2APLAUHDAC1HDAC2
SCHEMBL31021 0.86 HTR6 (0.73) HTR6KMT2APLAUHDAC1HDAC2
SCHEMBL29509279 0.86 HTR6 (0.73) HTR6KMT2APLAUHDAC1HDAC2
SCHEMBL6085799 0.84 HTR6 (0.70) HTR6KMT2APLAUHDAC1HDAC2
SCHEMBL2580966 0.84 HTR6 (0.70) HTR6KMT2APLAUHDAC1HDAC2
SCHEMBL3844137 0.84 HTR6 (0.70) HTR6KMT2APLAUHDAC1HDAC2
SCHEMBL6087734 0.84 HTR6 (0.70) HTR6KMT2APLAUHDAC1HDAC2
SCHEMBL21335591 0.84 HTR6 (0.70) HTR6KMT2APLAUHDAC1HDAC2
SCHEMBL31258083 0.84 HTR6 (0.70) HTR6KMT2APLAUHDAC1HDAC2
SCHEMBL257765 0.84 HTR6 (0.70) HTR6KMT2APLAUHDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114727985-A Anticancer agent 得克萨斯农业及机械体系综合大学 2022-07-08 CN claimed
US-20240254089-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2024-08-01 US disclosed
EP-4213839-A2 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS ESCIENT PHARMACEUTICALS, INC. (US) 2023-07-26 EP disclosed
CN-116438162-A Modulators of MAS-related G protein receptor X4 and related products and methods 伊赛恩特制药公司 2023-07-14 CN disclosed
EP-3298003-B1 BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2023-04-19 EP disclosed
CN-114767866-B Application of NURR1 gene as target in preparation of non-alcoholic fatty liver disease treatment drug 浙江大学 2023-04-07 CN disclosed
CN-115484822-A Methods for treating endometriosis 得克萨斯农业及机械体系综合大学 2022-12-16 CN disclosed
CN-114727985-A Anticancer agent 得克萨斯农业及机械体系综合大学 2022-07-08 CN disclosed
WO-2022061008-A2 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS ESCIENT PHARMACEUTICALS, INC. (US) 2022-03-24 WO disclosed
WO-2022061008-A2 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS ESCIENT PHARMACEUTICALS, INC. (US) 2022-03-24 WO disclosed
WO-2002010152-A2 NOVEL INDOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS ZENTARIS AG (DE) 2002-02-07 WO disclosed
WO-2002008225-A1 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY NOVUSPHARMA S.P.A. (IT) 2002-01-31 WO disclosed
WO-2001047916-A1 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY NOVUSPHARMA S.P.A. (IT) 2001-07-05 WO disclosed
US-5245046-A α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents THE UPJOHN COMPANY (US) 1993-09-14 US disclosed
EP-0375133-A1 Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents THE UPJOHN COMPANY (US) 1990-06-27 EP disclosed
WO-1990005721-A1 ALPHA-AMINO-INDOLE-3-ACETIC ACIDS USEFUL AS ANTI-DIABETIC, ANTI-OBESITY AND ANTI-ATHEROSCLEROTIC AGENTS THE UPJOHN COMPANY (US) 1990-05-31 WO disclosed
EP-0072932-B1 PIPERAZINONES, THEIR PREPARATION AND USE CASSELLA Aktiengesellschaft (DE) 1990-01-17 EP disclosed
US-4598079-A MEMORY DISORDERS CASSELLA AKTIENGESELLSCHAFT (DE) 1986-07-01 US disclosed
EP-0076713-A1 Aminomethyl-1H-indole-4-methanol derivatives and their salts, process and intermediates for their preparation, their use as medicines and compositions containing them ROUSSEL-UCLAF (FR) 1983-04-13 EP disclosed
EP-0072932-A2 Piperazinones, their preparation and use CASSELLA Aktiengesellschaft (DE) 1983-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254089-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS MRGPRX4, MRGPRX1, MRGPRX2 HTR6 553/4885KMT2A 3422/4885PLAU 2326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.